Spots Global Cancer Trial Database for palbociclib
Every month we try and update this database with for palbociclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. | NCT06086340 | Breast Cancer | Palbociclib Aromatase Inhib... | 65 Years - | Pfizer | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | NCT02022982 | KRAS Mutant Non... Solid Tumors | Palbociclib PD-0325901 | 18 Years - | Dana-Farber Cancer Institute | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer | NCT04874025 | Breast Cancer | Ibrance | 18 Years - | Hospital San Carlos, Madrid | |
| Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC | NCT03184090 | Metastatic Brea... | Palbociclib Endocrine thera... | 18 Years - | MedSIR | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | NCT03454035 | Tumor, Solid Pancreatic Canc... Melanoma | Ulixertinib Palbociclib | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | NCT01942135 | Metastatic Brea... | Palbociclib Fulvestrant Placebo Fulvestrant | 18 Years - | Pfizer | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET | NCT04992156 | Metastatic Brea... | Palbociclib | 18 Years - 70 Years | Fudan University | |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | NCT03526250 | Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... | Laboratory Biom... Palbociclib Pharmacological... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer | NCT04191499 | Breast Cancer | Inavolisib Placebo Palbociclib Fulvestrant | 18 Years - | Hoffmann-La Roche | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | NCT02897375 | Solid Neoplasm Stage III Pancr... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Non-Sm... Stage IVA Pancr... Stage IVB Pancr... Sarcoma Colorectal Canc... Head and Neck C... Cancer of Unkno... Bladder Cancer Ovarian Cancer | Carboplatin Cisplatin Palbociclib | 18 Years - | Emory University | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | NCT02296801 | Breast Cancer Breast Carcinom... Breast Tumors | Letrozole palbociclib | 18 Years - | NSABP Foundation Inc | |
| Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS) | NCT06113809 | Undifferentiate... | Palbociclib Pembrolizumab | 12 Years - | University of Iowa | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | NCT06188520 | ER+ HER2- Advan... High-grade Sero... | AZD8421 Camizestrant Ribociclib Palbociclib Abemaciclib | 18 Years - | AstraZeneca | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | NCT02530320 | Oligodendroglio... Oligoastrocytom... | Palbociclib | 18 Years - | Grupo Español de Investigación en Neurooncología | |
| Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | NCT04524728 | Breast Neoplasm Malign... Female | Palbociclib Letrozole 2.5mg Fulvestrant | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) | NCT03065621 | Breast Cancer F... | Palbociclib | 18 Years - | Jules Bordet Institute | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). | NCT03355157 | Metastatic Brea... | Palbociclib / C... | 18 Years - | German Breast Group | |
| Palbociclib In Progressive Brain Metastases | NCT02896335 | Metastatic Mali... | Palbociclib | 18 Years - | Massachusetts General Hospital | |
| A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel. | NCT04671615 | Metastatic Brea... | palbociclib | 18 Years - 99 Years | Pfizer | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy | NCT04736576 | Breast Cancer | Wearable device | 20 Years - | Pfizer | |
| Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | NCT03900884 | Breast Neoplasm... | Venetoclax Palbociclib Letrozole | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China | NCT04526028 | Breast Cancer Fulvestrant Palbociclib | Fulvestrant Inj... Palbociclib | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT03709082 | HER2-positive B... Breast Cancer M... | Palbociclib 75m... Letrozole 2.5mg T-DM1 Palbociclib 100... Palbociclib 125... Palbociclib | 18 Years - | University of Kansas Medical Center | |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | NCT02897375 | Solid Neoplasm Stage III Pancr... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Non-Sm... Stage IVA Pancr... Stage IVB Pancr... Sarcoma Colorectal Canc... Head and Neck C... Cancer of Unkno... Bladder Cancer Ovarian Cancer | Carboplatin Cisplatin Palbociclib | 18 Years - | Emory University | |
| A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | NCT05468697 | Renal Cell Carc... | Belzutifan Palbociclib | 18 Years - | Merck Sharp & Dohme LLC | |
| Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe | NCT04109261 | Breast Cancer | Palbociclib | 18 Years - 100 Years | Hospital San Carlos, Madrid | |
| A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor | NCT03219554 | Thymic Cancer | Palbociclib | 18 Years - | Samsung Medical Center | |
| Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02785939 | CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo... | Docetaxel Laboratory Biom... Palbociclib | 18 Years - | SWOG Cancer Research Network | |
| Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone | NCT05012644 | Metastatic Brea... | Palbociclib + a... Aromatase inhib... | - | Pfizer | |
| Biomarker-based Study in R/M SCCHN | NCT03088059 | Carcinoma, Squa... | Afatinib Palbociclib standard of car... IPH2201 Durvalumab Niraparib INCAGN01876 | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy | NCT04318223 | Metastatic Brea... Locally Advance... | Palbociclib | 18 Years - 64 Years | Consorzio Oncotech | |
| Study of Palbociclib in MLL-rearranged Acute Leukemias | NCT02310243 | Acute Myeloid L... Acute Lymphobla... | Palbociclib | 18 Years - | University of Ulm | |
| A Study of ZN-c5 in Subjects With Breast Cancer | NCT03560531 | Breast Cancer | ZN-c5 Palbociclib | 18 Years - | Zeno Alpha Inc. | |
| A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | NCT02592746 | Metastatic Brea... | Palbociclib Exemestane Leuprolide Acet... Capecitabine | 19 Years - | Samsung Medical Center | |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | NCT04606446 | Locally Advance... Locally Advance... Locally Advance... | PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060 | 18 Years - | Pfizer | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | NCT03792256 | Leukemia, Lymph... Lymphoblastic L... T-cell Lymphoma T-cell Leukemia Recurrent Disea... Acute Leukemia | Palbociclib Cytarabine Methotrexate Hydrocortisone Doxorubicin Prednisolone Vincristine Pegaspargase Hydrocortisone Prednisone | 12 Months - 31 Years | Children's Oncology Group | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | NCT04047758 | Breast Cancer | Palbociclib + L... Letrozole | 18 Years - 70 Years | Shengjing Hospital | |
| Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02785939 | CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo... | Docetaxel Laboratory Biom... Palbociclib | 18 Years - | SWOG Cancer Research Network | |
| Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | NCT04047758 | Breast Cancer | Palbociclib + L... Letrozole | 18 Years - 70 Years | Shengjing Hospital | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | NCT03322215 | Breast Cancer M... | Palbociclib Fulvestrant Capecitabine | 18 Years - | Karolinska University Hospital | |
| Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | NCT03774472 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Hydroxychloroqu... Letrozole Palbociclib | 18 Years - | M.D. Anderson Cancer Center | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | NCT03454035 | Tumor, Solid Pancreatic Canc... Melanoma | Ulixertinib Palbociclib | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | NCT03284957 | Breast Cancer | Amcenestrant Palbociclib Alpelisib Everolimus Abemaciclib | 18 Years - | Sanofi | |
| Study of Palbociclib in MLL-rearranged Acute Leukemias | NCT02310243 | Acute Myeloid L... Acute Lymphobla... | Palbociclib | 18 Years - | University of Ulm | |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | NCT06126276 | Malignant Femal... Malignant Solid... Recurrent Malig... Recurrent Malig... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Neratinib Malea... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | NCT05554367 | Malignant Solid... Ovarian Low Gra... Pancreatic Carc... Stage IV Ovaria... Stage IV Pancre... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Palbociclib | 18 Years - | National Cancer Institute (NCI) | |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan | NCT05399329 | Breast Cancer | Palbociclib Endocrine thera... | 20 Years - | Pfizer | |
| Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy | NCT04137640 | Breast Cancer | palbociclib com... epirubicin comb... | 18 Years - 70 Years | Shengjing Hospital | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | NCT03981614 | Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Ca... | Binimetinib Palbociclib Trifluridine an... | 18 Years - | Academic and Community Cancer Research United | |
| Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients | NCT04858997 | Breast Neoplasm... | Palbociclib AI | 18 Years - | Zhejiang Cancer Hospital | |
| DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer | NCT04567420 | Breast Cancer | Palbociclib Fulvestrant Adjuvant Therap... | - | Criterium, Inc. | |
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | NCT04288089 | Receptors, Estr... Genes, Erbb-2 Breast Neoplasm... | Palbociclib (75... H3B-6545 (150, ... | 18 Years - | Eisai Inc. | |
| A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | NCT04872608 | Metastatic Brea... Unresectable Br... | Letrozole Palbociclib Onapristone ER | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
